Presbyopia Therapeutics – Epidemiology and Pipeline Analysis, 2020

Chapter 1. Research Background

1.1 Research Objectives

1.2 Definition

1.3 Research Scope

1.3.1 Pipeline Drugs by Phase

1.3.2 Pipeline Analysis by Molecule Type

1.3.3 Pipeline Analysis by Route of Administration

1.3.4 Pipeline Analysis by Product Type

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1 Breakdown of Primary Research Respondents

2.2.1.1 By industry participant

2.2.1.2 By geography

2.2.1.3 By designation

2.2.2 Key Opinion Leaders (KOLs) Validation

2.3 Coverage of Epidemiology Analysis

2.4 Forecast Methodology

2.5 Assumptions for the Study

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1 Disease Overview

4.1.1 Theories of Accommodation

4.1.1.1 The Helmholtz theory

4.1.1.2 The Schachar theory

4.1.1.3 The Coleman theory

4.2 Classification of Presbyopia

4.3 Signs and Symptoms

4.4 Diagnosis

4.5 Etiology of Presbyopia

4.6 Prognosis and Follow-up

4.7 Treatment

4.8 Key Drivers

4.8.1 Novel Delivery Systems/Devices

4.8.2 Positive Clinical Results

4.8.3 Growing Geriatric Population

4.9 Key Barriers

4.9.1 Stringent Regulations

4.9.2 Safety Concerns

4.9.3 Unavailability of Marketed Products

4.10 Drug Designations

4.11 Presbyopia Therapeutics Pipeline Drugs Snapshot

4.11.1 Pipeline Drugs Snapshot, By Phase

4.11.2 Pipeline Drugs Snapshot, By Molecule Type

4.11.3 Pipeline Drugs Snapshot, By Product Type

4.11.4 Pipeline Drugs Snapshot by Company

Chapter 5. Presbyopia Epidemiology Forecast in 7MMs

5.1 7MMs

5.1.1 Prevalence of Presbyopia

5.1.2 Prevalence of Presbyopia, By Gender

5.1.3 Prevalence of Presbyopia, By Age-Group

5.2 U.S.

5.2.1 Prevalence of Presbyopia

5.2.2 Prevalence of Presbyopia, By Gender

5.2.3 Prevalence of Presbyopia, By Age-Group

5.3 EU5

5.3.1 Prevalence of Presbyopia

5.3.2 Prevalence of Presbyopia, By Gender

5.3.3 Prevalence of Presbyopia, By Age-Group

5.3.4 Prevalence of Presbyopia, by Country

5.3.4.1 Germany

5.3.4.1.1 Prevalence of presbyopia

5.3.4.1.2 Prevalence of presbyopia, by gender

5.3.4.1.3 Prevalence of presbyopia, by age-group

5.3.4.2 France

5.3.4.2.1 Prevalence of presbyopia

5.3.4.2.2 Prevalence of presbyopia, by gender

5.3.4.2.3 Prevalence of presbyopia, by age-group

5.3.4.3 U.K.

5.3.4.3.1 Prevalence of presbyopia

5.3.4.3.2 Prevalence of presbyopia, by gender

5.3.4.3.3 Prevalence of presbyopia, by age-group

5.3.4.4 Italy

5.3.4.4.1 Prevalence of presbyopia

5.3.4.4.2 Prevalence of presbyopia, by gender

5.3.4.5 Spain

5.3.4.5.1 Prevalence of presbyopia

5.3.4.5.2 Prevalence of presbyopia, by gender

5.3.4.5.3 Prevalence of presbyopia, by age-group

5.4 Japan

5.4.1 Prevalence of Presbyopia

5.4.2 Prevalence of Presbyopia, By Gender

5.4.3 Prevalence of Presbyopia, By Age-Group

Chapter 6. Presbyopia Therapeutics Pipeline Analysis by Phase

6.1 Phase III

6.1.1 Presbysol

6.1.1.1 Clinical trials

6.1.1.2 Clinical trial results

6.1.1.3 Acquisition

6.2 Phase II

6.2.1 UNR844

6.2.1.1 Clinical trials

6.2.1.2 Clinical trial results

6.2.1.3 Acquisition

6.2.1.4 Investigational new drug (IND) application

6.2.2 Xxxx

6.2.2.1 Clinical trials

6.2.2.2 Clinical trial results

6.2.2.3 Financing

6.2.2.4 Patent

6.2.3 Xxxx

6.2.3.1 Clinical trials

6.2.3.2 Clinical trial results

6.2.3.3 Acquisition

6.2.4 Xxxx

6.2.4.1 Technology

6.2.5 Xxxx

6.2.5.1 Clinical trials

6.2.5.2 Clinical trial results

6.2.5.3 Patent

6.3 Phase I

6.3.1 Xxxx

6.3.1.1 Clinical trials

6.3.1.2 Clinical trial result

6.3.1.3 Financing

6.4 Pre-clinical

6.4.1 Lanosterol

6.4.1.1 Agreement

6.4.1.2 Name change

6.4.2 Xxxx

6.4.2.1 Pre-clinical studies

6.4.2.2 Financing

6.4.3 Xxxx

Chapter 7. Clinical Trials Analysis

7.1 Clinical Trials, By Region

Chapter 8. Regulatory Framework for Drug Approval

8.1 U.S.

8.2 Europe

8.2.1 Centralized Procedure

8.2.2 Mutual Recognition Procedure

8.2.3 Decentralized Procedure

8.2.4 Nationalized Procedure

8.3 Japan

Chapter 9. Competitive Landscape

9.1 Summary of Strategic Developments

9.2 Attribute Analysis

9.3 Expected Launch Time of Clinical Stage Products

9.4 SWOT Analysis

Chapter 10. Company Profiles

10.1 Xxxx

10.1.1 Business Overview

10.1.2 Products and Service Offerings

10.2 Ocuphire Pharma Inc.

10.2.1 Business Overview

10.2.2 Products and Service Offerings

10.3 Xxxx

10.3.1 Business Overview

10.3.2 Products and Service Offerings

10.4 Novartis AG

10.4.1 Business Overview

10.4.2 Product and Service Offerings

10.4.3 Key Financial Summary

10.5 Allergan plc

10.5.1 Business Overview

10.5.2 Product and Service Offerings

10.6 Kubota Pharmaceutical Holdings Co. Ltd.

10.6.1 Business Overview

10.6.2 Product and Service Offerings

10.6.3 Key Financial Summary

10.7 Xxxx

10.7.1 Business Overview

10.7.2 Product and Service Offerings

10.8 Xxxx

10.8.1 Business Overview

10.8.2 Product and Service Offerings

10.9 Xxxx

10.9.1 Business Overview

10.9.2 Product and Service Offerings

Chapter 11. Appendix

11.1 Recently Organized/Held Seminars and Conferences

11.2 Upcoming Conferences

11.3 Abbreviations

11.4 Sources & References

11.5 Related Reports

 

LIST OF TABLES

 

TABLE 1: DIAGNOSIS OF PRESBYOPIA

TABLE 2: COMMON RISK FACTORS FOR PRESBYOPIA

TABLE 3: PREVALENT CASES OF PRESBYOPIA IN 7MMS, MILLION (2014–2019)

TABLE 4: PREVALENT CASES OF PRESBYOPIA IN 7MMS, MILLION (2020–2030)

TABLE 5: PREVALENCE OF PRESBYOPIA IN 7MMS, BY GENDER, MILLION (2014–2019)

TABLE 6: PREVALENCE OF PRESBYOPIA IN 7MMS, BY GENDER, MILLION (2020–2030)

TABLE 7: PREVALENCE OF PRESBYOPIA IN 7MMS, BY AGE-GROUP, MILLION (2014–2019)

TABLE 8: PREVALENCE OF PRESBYOPIA IN 7MMS, BY AGE-GROUP, MILLION (2020–2030)

TABLE 9: PREVALENT CASES OF PRESBYOPIA IN THE U.S., MILLION (2014–2019)

TABLE 10: PREVALENT CASES OF PRESBYOPIA IN THE U.S., MILLION (2020–2030)

TABLE 11: PREVALENCE OF PRESBYOPIA IN THE U.S., BY GENDER, MILLION (2014–2019)

TABLE 12: PREVALENCE OF PRESBYOPIA IN THE U.S., BY GENDER, MILLION (2020–2030)

TABLE 13: PREVALENCE OF PRESBYOPIA IN THE U.S., BY AGE-GROUP, MILLION (2014–2019)

TABLE 14: PREVALENCE OF PRESBYOPIA IN THE U.S., BY AGE-GROUP, MILLION (2020–2030)

TABLE 15: PREVALENT CASES OF PRESBYOPIA IN THE EU5, MILLION (2014–2019)

TABLE 16: PREVALENT CASES OF PRESBYOPIA IN THE EU5, MILLION (2020–2030)

TABLE 17: PREVALENCE OF PRESBYOPIA IN THE EU5, BY GENDER, MILLION (2014–2019)

TABLE 18: PREVALENCE OF PRESBYOPIA IN THE EU5, BY GENDER, MILLION (2020–2030)

TABLE 19: PREVALENCE OF PRESBYOPIA IN THE EU5, BY AGE-GROUP, MILLION (2014–2019)

TABLE 20: PREVALENCE OF PRESBYOPIA IN THE EU5, BY AGE-GROUP, MILLION (2020–2030)

TABLE 21: PREVALENT CASES OF PRESBYOPIA IN GERMANY, MILLION (2014–2019)

TABLE 22: PREVALENT CASES OF PRESBYOPIA IN GERMANY, MILLION (2020–2030)

TABLE 23: PREVALENCE OF PRESBYOPIA IN GERMANY, BY GENDER, MILLION (2014–2019)

TABLE 24: PREVALENCE OF PRESBYOPIA IN GERMANY, BY GENDER, MILLION (2020–2030)

TABLE 25: PREVALENCE OF PRESBYOPIA IN GERMANY, BY AGE-GROUP, MILLION (2014–2019)

TABLE 26: PREVALENCE OF PRESBYOPIA IN GERMANY, BY AGE-GROUP, MILLION (2020–2030)

TABLE 27: PREVALENT CASES OF PRESBYOPIA IN FRANCE, MILLION (2014–2019)

TABLE 28: PREVALENT CASES OF PRESBYOPIA IN FRANCE, MILLION (2020–2030)

TABLE 29: PREVALENCE OF PRESBYOPIA IN FRANCE, BY GENDER, MILLION (2014–2019)

TABLE 30: PREVALENCE OF PRESBYOPIA IN FRANCE, BY GENDER, MILLION (2020–2030)

TABLE 31: PREVALENCE OF PRESBYOPIA IN FRANCE, BY AGE-GROUP, MILLION (2014–2019)

TABLE 32: PREVALENCE OF PRESBYOPIA IN FRANCE, BY AGE-GROUP, MILLION (2020–2030)

TABLE 33: PREVALENT CASES OF PRESBYOPIA IN THE U.K., MILLION (2014–2019)

TABLE 34: PREVALENT CASES OF PRESBYOPIA IN THE U.K., MILLION (2020–2030)

TABLE 35: PREVALENCE OF PRESBYOPIA IN THE U.K., BY GENDER, MILLION (2014–2019)

TABLE 36: PREVALENCE OF PRESBYOPIA IN THE U.K., BY GENDER, MILLION (2020–2030)

TABLE 37: PREVALENCE OF PRESBYOPIA IN THE U.K., BY AGE-GROUP, MILLION (2014–2019)

TABLE 38: PREVALENCE OF PRESBYOPIA IN THE U.K., BY AGE-GROUP, MILLION (2020–2030)

TABLE 39: PREVALENT CASES OF PRESBYOPIA IN ITALY, MILLION (2014–2019)

TABLE 40: PREVALENT CASES OF PRESBYOPIA IN ITALY, MILLION (2020–2030)

TABLE 41: PREVALENCE OF PRESBYOPIA IN ITALY, BY GENDER, MILLION (2014–2019)

TABLE 42: PREVALENCE OF PRESBYOPIA IN ITALY, BY GENDER, MILLION (2020–2030)

TABLE 43: PREVALENT CASES OF PRESBYOPIA IN SPAIN, MILLION (2014–2019)

TABLE 44: PREVALENT CASES OF PRESBYOPIA IN SPAIN, MILLION (2020–2030)

TABLE 45: PREVALENCE OF PRESBYOPIA IN SPAIN, BY GENDER, MILLION (2014–2019)

TABLE 46: PREVALENCE OF PRESBYOPIA IN SPAIN, BY GENDER, MILLION (2020–2030)

TABLE 47: PREVALENCE OF PRESBYOPIA IN SPAIN, BY AGE-GROUP, MILLION (2014–2019)

TABLE 48: PREVALENCE OF PRESBYOPIA IN SPAIN, BY AGE-GROUP, MILLION (2020–2030)

TABLE 49: PREVALENT CASES OF PRESBYOPIA IN JAPAN, MILLION (2014–2019)

TABLE 50: TOTAL PREVALENT CASES OF PRESBYOPIA IN JAPAN, MILLION (2020–2030)

TABLE 51: PREVALENCE OF PRESBYOPIA IN JAPAN, BY GENDER, MILLION (2014–2019)

TABLE 52: PREVALENCE OF PRESBYOPIA IN JAPAN, BY GENDER, MILLION (2020–2030)

TABLE 53: PREVALENCE OF PRESBYOPIA IN JAPAN, BY AGE-GROUP, MILLION (2014–2019)

TABLE 54: PREVALENCE OF PRESBYOPIA IN JAPAN, BY AGE-GROUP, MILLION (2020–2030)

TABLE 55: DESCRIPTION OF PRESBYSOL

TABLE 56: CLINICAL TRIALS OF PRESBYSOL

TABLE 57: DESCRIPTION OF UNR844

TABLE 58: CLINICAL TRIALS OF UNR844

TABLE 59: DESCRIPTION OF XXXX

TABLE 60: CLINICAL TRIALS OF XXXX

TABLE 61: DESCRIPTION OF XXXX

TABLE 62: CLINICAL TRIALS OF XXXX

TABLE 63: DESCRIPTION OF XXXX

TABLE 64: DESCRIPTION OF XXXX

TABLE 65: CLINICAL TRIALS OF XXXX

TABLE 66: CLINICAL TRIAL SUMMARY

TABLE 67: DESCRIPTION OF NYXOL

TABLE 68: DESCRIPTION OF LANOSTEROL

TABLE 69: DESCRIPTION OF XXXX

TABLE 70: DESCRIPTION OF XXXX

TABLE 71: COLLABORATIONS AND LICENSING AGREEMENTS

TABLE 72: MERGERS & ACQUISITIONS

TABLE 73: ATTRIBUTE ANALYSIS OF PRESBYSOL, UNR844, XXXX, AND XXXX

TABLE 74: XXXX – AT A GLANCE

TABLE 75: PIPELINE PRODUCTS

TABLE 76: OCUPHIRE PHARMA INC. – AT A GLANCE

TABLE 77: PIPELINE PRODUCTS

TABLE 78: XXXX – AT A GLANCE

TABLE 79: NOVARTIS AG – AT A GLANCE

TABLE 80: NOVARTIS AG – KEY FINANCIAL SUMMARY

TABLE 81: ALLERGAN PLC – AT A GLANCE

TABLE 82: KUBOTA PHARMACEUTICAL HOLDINGS CO. LTD. – AT A GLANCE

TABLE 83: KUBOTA PHARMACEUTICAL HOLDINGS CO. LTD. – KEY FINANCIAL SUMMARY

TABLE 84: XXXX - AT A GLANCE

TABLE 85: XXXX - AT A GLANCE

TABLE 86: XXXX - AT A GLANCE

TABLE 87: CONFERENCES AND EVENTS

TABLE 88: UPCOMING SEMINARS AND CONFERENCES

 

LIST OF FIGURES

 

FIG 1 RESEARCH METHODOLOGY

FIG 2 BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY INDUSTRY PARTICIPANT

FIG 3 BREAKDOWN OF PRIMARY RESEARCH, BY GEOGRAPHY

FIG 4 BREAKDOWN OF PRIMARY RESEARCH, BY DESIGNATION

FIG 5 APPLICATION OF THE HELMHOLTZ THEORY OF ACCOMMODATION IN PRESBYOPIA

FIG 6 APPLICATION OF THE SCHACHAR THEORY OF ACCOMMODATION IN PRESBYOPIA

FIG 7 APPLICATION OF THE COLEMAN THEORY OF ACCOMMODATION IN PRESBYOPIA

FIG 8 PRESBYOPIC SURGICAL METHODS

FIG 9 PRESBYOPIA THERAPEUTICS PIPELINE DRUGS SNAPSHOT, BY PHASE (2019)

FIG 10 PRESBYOPIA THERAPEUTICS PIPELINE DRUGS SNAPSHOT, BY MOLECULE TYPE (2019)

FIG 11 PRESBYOPIA THERAPEUTICS PIPELINE DRUGS SNAPSHOT, BY PRODUCT TYPE

FIG 12 PRESBYOPIA THERAPEUTICS PIPELINE DRUGS SNAPSHOT, BY COMPANY

FIG 13 PREVALENT CASES OF PRESBYOPIA IN 7MMS, MILLION (2014-2030)

FIG 14 PREVALENCE OF PRESBYOPIA IN 7MMS, BY GENDER, MILLION (2014–2030)

FIG 15 PREVALENCE OF PRESBYOPIA IN 7MMS, BY AGE-GROUP, MILLION (2014–2030)

FIG 16 PREVALENT CASES OF PRESBYOPIA IN THE U.S., MILLION (2014-2030)

FIG 17 PREVALENCE OF PRESBYOPIA IN THE U.S., BY GENDER (2014–2030)

FIG 18 PREVALENCE OF PRESBYOPIA IN THE U.S., BY AGE-GROUP, MILLION (2014–2030)

FIG 19 PREVALENT CASES OF PRESBYOPIA IN THE EU5, MILLION (2014-2030)

FIG 20 PREVALENCE OF PRESBYOPIA IN THE EU5, BY GENDER, MILLION (2014–2030)

FIG 21 PREVALENCE OF PRESBYOPIA IN THE EU5, BY AGE-GROUP (2014–2030)

FIG 22 PREVALENT CASES OF PRESBYOPIA IN JAPAN, MILLION (2014-2030)

FIG 23 PREVALENCE OF PRESBYOPIA IN JAPAN, BY GENDER, MILLION (2014–2030)

FIG 24 PREVALENCE OF PRESBYOPIA IN JAPAN, BY AGE-GROUP, MILLION (2014–2030)

FIG 25 MODULATED PUPIL CONSTRICTION

FIG 26 CLINICAL TRIALS, BY REGION

FIG 27 DRUG DISCOVERY AND APPROVAL PROCESS (PRE-CLINICAL AND CLINICAL TRIALS STAGES)

FIG 28 DRUG APPROVAL PROCESS (NDA REVIEW AND POST-MARKETING STAGES)

FIG 29 NEW DRUG DEVELOPMENT AND APPROVAL PROCESS IN EU

FIG 30 MARKETING AUTHORIZATION PROCEDURES IN EU

FIG 31 CENTRALIZED PROCEDURE FOR DRUG APPROVAL

FIG 32 MUTUAL RECOGNITION PROCEDURE FOR DRUG APPROVAL

FIG 33 DECENTRALIZED PROCEDURE FOR DRUG APPROVAL

FIG 34 NEW DRUG DEVELOPMENT AND APPROVAL PROCESS IN JAPAN

FIG 35 EXPECTED LAUNCH TIME OF LATE CLINICAL STAGE PRODUCTS

FIG 36 NOVARTIS AG – REVENUE SPLIT BY BUSINESS DIVISION AND GEOGRAPHY (2019)